CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 3 enrolled
Drug / intervention
vitamin K1drug
Likely dose
vitamin K1 400 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02324686
NCT02324686Phase 2Completed
CompareCT.gov

Vitamin K Supplementation to Improve INR Stability in Patients on Hemodialysis Taking Warfarin for Atrial Fibrillation

University Health Network, Toronto·interventional·Posted Dec 24, 2014·Updated Feb 6, 2018

In Brief

A Phase 2 clinical trial evaluating vitamin K1 for End Stage Renal Failure on Dialysis and Atrial Fibrillation. Completed, enrolled 3 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether vitamin K supplementation will improve anticoagulation control in patients on hemodialysis taking warfarin for atrial fibrillation. Patients who participate will receive vitamin K1 three times a week on dialysis days for a period of four months. INR levels collected during this period will be compared to the four month period prior to receiving the vitamin K1 to determine if vitamin K improves the standard deviation of INRs and time in therapeutic range.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd Stage Renal Failure on Dialysis, Atrial Fibrillation
CountriesCanada
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 24, 2014
Enrollment StartJan 1, 2014
Primary CompletionDec 18, 2017
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 11.5 years ago

Interventions

vitamin K1drug

Vitamin K1 400 mcg orally three times a week on dialysis days for four months